Regeneron Pharmaceuticals, Inc. drugs
4 results
Evkeeza (evinacumab)
(evinacumab)Regeneron Pharmaceuticals, Inc.
Usage: EVKEEZA is indicated as an adjunct therapy for adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH). Its safety and effectiveness in other types of hypercholesterolemia, such as heterozygous familial hypercholesterolemia, have not been established.
Libtayo (cemiplimab-rwlc)
(cemiplimab-rwlc)Regeneron Pharmaceuticals, Inc.
Usage: LIBTAYO is indicated for the treatment of metastatic and locally advanced cutaneous squamous cell carcinoma (CSCC) in patients unsuitable for curative surgery or radiation. It is also used for locally advanced or metastatic basal cell carcinoma (BCC) post-hedgehog pathway inhibitor, and for specific cases of non-small cell lung cancer (NSCLC).
Praluent (alirocumab)
(alirocumab)Regeneron Pharmaceuticals, Inc.
Usage: PRALUENT® is indicated for reducing the risk of myocardial infarction, stroke, and unstable angina in adults with cardiovascular disease; lowering LDL-C in adults with primary hyperlipidemia and familial hypercholesterolemia; and for pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.
Veopoz (pozelimab)
(Pozelimab)Regeneron Pharmaceuticals, Inc.
Usage: VEOPOZ is used to treat adult and pediatric patients aged 1 year and older with CD55-deficient protein-losing enteropathy (PLE), commonly referred to as CHAPLE disease.